Latest Prometic Life Scienc (PFSCF) Headlines
Avivagen Announces Nomination of New Director Mr. G.F. Kym Anthony Standing for Election
ACCESSWIRE - Fri Feb 28, 7:02AM CST
OTTAWA, ONTARIO / February 28, 2014 / ACCESSWIRE / Avivagen Inc. (TSXV:VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces the nomination of a new Director, Mr. G.F. Kym Anthony, and the retirement of its current Chairman, Mr. Jacques Brault.
ProMetic Enters Into $1.6 Million Development Agreement With New Client
Marketwire - Thu Feb 06, 12:25PM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that its UK based subsidiary, ProMetic BioSciences Ltd. ("PBL"), has entered into a new agreement with a leading vaccines company, for the development of an affinity adsorbent and associated purification process for the production of a novel vaccine product.
ProMetic Announces the Appointment of its New Chief Medical Officer
Marketwire - Thu Feb 06, 5:31AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today the appointment of Dr. John Moran as its new Chief Medical Officer ("CMO"), effective as of March 1st, 2014.
ProMetic Achieves Key Plasma Protein Manufacturing Milestone
Marketwire - Wed Jan 22, 6:01AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today the achievement of the second manufacturing milestone related to its strategic agreement ("Agreement") with Hematech Biotherapeutics Inc. ("Hematech") triggering a $1.0 million payment to ProMetic. This milestone was achieved following the successful completion of the first large-scale production run at its ProMetic BioProduction Inc. ("PBP") plasma purification facility located in Laval, Quebec.
Bioseparation Systems for Global Biopharmaceutical Markets: 2013 Report
M2 - Tue Dec 17, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/8b887q/bioseparation) has announced the addition of the "Bioseparation Systems for Global Biopharmaceutical Markets: 2013 Report" report to their offering. Bioseparations systems can be categorized into three types: chromatography, membranes/filters and centrifuges. The demand for single use products is increasing and fueling growth of the global bioseparations market. New biosimilars are driving the increase in global biomanufacturing capacity. Blockbuster biologics are going off patent, leaving the market open for developing and manufacturing low cost biosimilars. This report provides market revenue size and growth rates for North America, Europe, Asia-Pacific (Japan, South Korea, Singapore) and the emerging BRICs (Brazil, Russia, India, China). Single-use products, manufacturing capacity, applications of bioseparations in downstream processing, downstream processing bottlenecks and emerging bioseparations technologies are covered in detail. The report also analyzes the competitive landscape, including key players' strengths and weaknesses, opportunities, gaps and industry trends. Detailed tables and charts with sales forecasts and marketshare data are also included. Scope of the Report - Single use products - Manufacturing capacity - Applications of bioseparations in downstream processing - Downstream processing bottlenecks - Emerging bioseparations technologies - Manufacturing capacity by biopharmaceutical company, CMO and region Key Topics Covered: 1. Introduction 2. Overview 3. Biologics in the Development Phase 4. Bioseparations Products and Systems 5. The Biopharmaceutical Manufacturing Process 6. Bioseparation Processes Used for Biologics Manufacturing 7. Global Bioseparation Market Analysis 8. The Global Bioseparations Market by Region 9. Competitive Landscape 10. Industry Analysis 11. Single-Use Bioseparations Systems and Products 12. Chromatography for Bioseparations 13. Filters and Membranes Used for Bioseparations 14. Industrial Centrifuges for Downstream Processing 15. Company Profiles Companies Mentioned: - Agilent Technologies - Alfa Wassermann Separation Technologies - Applied Biosystems Corporation (Life Technologies) - Asahi Kasei - Bio-Rad Laboratories - Carr Centritech - Celeros - DSM Biologics - Dow Chemical Company - Flottweg Separations Technology - G-Con Manufacturing - GE Healthcare Life Sciences - GEA Westfalia Separator Group - Hitachi Koki Co LTD - Knauer - Kronlab (YMC Europe) - Life Technologies - M Cuno - Meissner Filtration Products, Inc - Merck Millipore - Novasep Life Sciences Manufacturing Solutions - Novavax - NuSep Holdings Ltd - Pall Corporation - ProMetic Life Sciences Inc - Sartorius Stedim Biotech - SciLog - Spectrum Laboratories - Tarpon Biosystems - Tosoh Bioscience - US Filter Control Systems, Inc - Waters Corporation For more information visit http://www.researchandmarkets.com/research/8b...separation
ProMetic Announces Operational Launch of its Plasma Purification Facility
Marketwire - Wed Dec 11, 6:01AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation") is proud to announce that it has achieved a major corporate milestone, by successfully completing the first commercial-scale production run at its ProMetic BioProduction Inc. ("PBP") plasma purification facility located in Laval, Quebec. This production run was completed on schedule and generated better than expected results.
ProMetic Receives $5.1 Million Purchase Order from Multinational Client
Marketwire - Tue Nov 19, 6:01AM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that it has received a $5.1 million purchase order for the supply of affinity resin from an existing client, a global leader in the biotherapeutics industry.
ProMetic Reports its Third Quarter 2013 Highlights and Financial Results
Marketwire - Thu Nov 14, 6:01AM CST
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today reported revenues of $6.0 million and an EBITDA loss of $2.0 million for the third quarter ended September 30, 2013. 2013 year-to-date revenues totaled $15.6 million compared to $15.0 million for the same 2012 period.
ProMetic's PBI-4050 Shown to Reduce Heart Fibrosis
Marketwire - Tue Nov 12, 6:01AM CST
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") presented new preclinical data at the 2013 American Society of Nephrology ("ASN") annual meeting held in Atlanta on November 7-10, 2013.
ProMetic to Report its Third Quarter 2013 Highlights and Financial Results and Hold Conference Call/Webcast
Marketwire - Mon Nov 11, 4:00PM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation") today announced that it will report its financial results for the third quarter ended September 30, 2013 on Thursday November 14, 2013 before market trading hours.
ProMetic Announces the Closing of its Common Share Offering
Marketwire - Thu Nov 07, 9:07AM CST
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") is pleased to announce that it has closed its previously announced public offering (the "Offering") of common shares in the capital of the Corporation (the "Common Shares"). The Offering was conducted on a best efforts basis by a syndicate of agents led by Paradigm Capital Inc. and including Beacon Securities Limited, D&D Securities Inc. and Cormark Securities Inc. (collectively the "Agents").